This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cutting-edge approaches to trial and study design, technology, sourcing, data disclosure and medical communications.

Clinical trials meet COVID-19: Lessons learnt and challenges ahead - VIDEO PANEL

Share this article

The spread of COVID-19 across the globe had huge impacts on clinical trials in 2020 and beyond. Lockdowns meant that many patients could no longer travel for studies, whilst social distancing and safety protocols changed the way trials ran.  At the same time, the world's attention was turning to clinical trials in the hope that vaccines would be approved in record time.

One of the highlights of Clinical Trials Europe Virtual 2020, was a live panel of leading industry experts discussing the lessons learnt and challenges ahead in combating COVID-19. Watch the full session at the top of this page.

The panel featured:

  • MODERATOR: Pamela Tenaerts, Executive Director, Clinical Trials Transformation Initiative (CTTI)
  • Elizabeth Eagling-Vose, Director, Head of Clinical Operations, Vaccitech
  • Robert Dingwall, Professor of Sociology, Nottingham Trent University
  • Bodo Lutz, Clinical Risk Management and Data Integrity QA, Novartis
  • Fiona Maini, Principal - Global Compliance and Strategy, Medidata
  • Janis Little, Vice President, R&D Quality, Moderna
  • Oren Cohen, Chief Medical Officer and Head of Global Clinical Pharmacology Services, Covance

The panel discuss the race to develop a vaccine for COVID-19, how technologies such as AI and modelling can be used to speed up the development timelines and the ethical and regulatory considerations around it. They discuss evidence of companies jumping the gun and trying to get product onto the market too quickly, and the subsequent enforcement ramping up against this - what will the long lasting regulatory impact look like?

And post-approval, how can we scale the manufacture of vaccines significantly and get global co-operation in the roll-out, whilst maintaining public confidence in the management of vaccine development.

Away from vaccine development, the panel discuss supply change management and keeping clinical labs open in order for clinical trials to run during a pandemic.

Watch the full session at the top of this page.

Share this article

Upcoming event

Clinical Trials Europe

29 - 30 Nov 2023, *IN-PERSON EVENT ONLY*

Streamline & Simplify Your Clinical Trials

Go to site